Hightide Therapeutics Inc (HK:2511) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
HighTide Therapeutics Inc. has successfully completed patient enrollment for its Phase III clinical trial comparing HTD1801 with dapagliflozin for treating Type 2 Diabetes Mellitus. This trial, which involves 358 participants, aims to assess the effectiveness of HTD1801 in improving glucose metabolism and insulin resistance. Final results are anticipated in 2025, marking a significant milestone in the company’s development of innovative therapies for metabolic diseases.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue